ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. It operates through the Generics, Established Brands, and Other, and Rare Disease segments. The Generics, Established Brands, and Other segment consists of contract manufactured products, development services, royalties, and other. The Rare Disease segment involves the operations related to Cortrophin Gel. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.
Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No trial data available
No approval data available
- ANI Pharmaceuticals reported record quarterly revenue of $266 million, a 25.9% year-over-year increase that beat analyst estimates of $259.8 million. - Cortrophin Gel sales grew 43% year-over-year, driven by the company's largest-ever rare disease sales force expansion to roughly 180 representatives targeting acute gouty arthritis. - Management revised Cortrophin Gel annual guidance to $520–$540 million while reaffirming full-year revenue guidance of $1.11 billion and adjusted EPS of $9.44 at the midpoint. - Rare Disease revenues are projected to approach 60% of total company turnover by year-end 2026, with the Phase IV SYNCHRONICITY trial for ILUVIEN expected to read out in Q4 2026.
- ANI Pharmaceuticals (ANIP) is highlighted by analysts with a bull case suggesting the stock could be worth over five times its current trading price. - The positive outlook is linked to developments involving ILUVIEN, an intravitreal implant for diabetic macular edema, though specific clinical data are not detailed in the source materials. - A comprehensive fundamental analysis identifies four key rewards and three warning signs that could impact the investment decision for ANI Pharmaceuticals. - The analysis is provided by Simply Wall St and is based on historical data and analyst forecasts, not constituting financial advice.
- ANI Pharmaceuticals' Phase 4 SYNCHRONICITY trial of ILUVIEN met both co-primary endpoints with statistical significance at six months in 108 patients with chronic non-infectious uveitis affecting the posterior segment. - Patients gained a mean of 3.6 ETDRS letters in best corrected visual acuity (p=0.0077) and achieved a 157.5-micron reduction in central subfield thickness (p<0.0001) from baseline. - The safety profile was consistent with prior fluocinolone acetonide trials, with ocular hypertension in 6% of patients and 7% requiring laser or surgical IOP-lowering intervention. - Full 24-month durability data will be presented at medical conferences in Q4 2026, representing the key commercial inflection point for ILUVIEN's uveitis franchise.
- ANI Pharmaceuticals received FDA approval for its Abbreviated New Drug Application and launched generic Isosorbide Mononitrate Tablet USP in 10 mg and 20 mg strengths. - The generic product serves as an alternative to the reference listed drug Monoket® and represents a limited-competition product opportunity. - CEO Nikhil Lalwani emphasized the launch reinforces ANI's R&D capabilities and commitment to maintaining a steady cadence of new product launches. - The approval highlights ANI's strategy to bring accessible, high-quality generic therapeutics to patients in need through its Generics business division.
- ANI Pharmaceuticals' NEW DAY trial of ILUVIEN for diabetic macular edema failed to meet its primary endpoint of reducing supplemental aflibercept injections compared to aflibercept alone (2.4 vs. 2.5 injections, p=0.756). - A post-hoc analysis of patients without protocol deviations showed ILUVIEN significantly reduced supplemental injections (1.8 vs. 2.5, p=0.029), resulting in fewer total injections over 18 months. - ILUVIEN demonstrated a statistically significant longer time to first supplemental injection (185.4 vs. 132.8 days, p<0.001) and showed non-inferiority in visual acuity outcomes. - The safety profile was consistent with previous studies, with 41% of ILUVIEN patients experiencing treatment-related adverse events, primarily cataracts and increased intraocular pressure.
- The global uveitis treatment market reached approximately $1.47 billion in 2022 across seven major markets and is projected to grow significantly through 2034, driven by emerging therapies and expanded treatment indications. - ANI Pharmaceuticals received FDA approval for an expanded ILUVIEN label to include chronic non-infectious uveitis affecting the posterior segment, marking a significant regulatory milestone for the company's ophthalmology portfolio. - Oculis Holding achieved positive Phase 2 results with OCS-05 for acute optic neuritis, meeting primary safety endpoints and demonstrating statistical significance on key efficacy measures. - Multiple pharmaceutical companies including Priovant Therapeutics, Trethera Corporation, and others are advancing novel therapies through clinical development, with several candidates receiving FDA Fast Track and orphan drug designations.
- The FDA has approved an expanded label for ILUVIEN (fluocinolone acetonide intravitreal implant) to include treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, in addition to its existing diabetic macular edema indication. - ANI Pharmaceuticals plans to begin marketing ILUVIEN under the combined label later this year, enhancing treatment options for patients with these serious ocular conditions. - The company has extended its supply agreement with Siegfried Holding AG through 2029, including upgrades to manufacturing equipment and significant capacity expansion to ensure product availability.
- ANI Pharmaceuticals receives FDA approval for a new prefilled syringe format of Cortrophin Gel, available in 40 USP units/0.5 mL and 80 USP units/mL single-dose options. - The new presentation simplifies administration for patients using Cortrophin Gel therapy while maintaining its established efficacy in treating various autoimmune and inflammatory conditions. - Commercial availability is expected in the second quarter of 2025, expanding ANI's Rare Disease portfolio and improving treatment accessibility for patients.
- ANI Pharmaceuticals has launched Prucalopride Tablets, a generic version of Motegrity, after receiving FDA approval and a Competitive Generic Therapy (CGT) designation. - Prucalopride, a selective 5-HT4 receptor agonist, enhances colon muscle movement to alleviate infrequent bowel movements in adults with chronic idiopathic constipation. - Clinical trials have demonstrated prucalopride's efficacy and safety in treating chronic constipation, showing a higher proportion of patients achieving at least 3 spontaneous bowel movements per week compared to placebo. - Real-world studies suggest prucalopride has higher treatment persistence and adherence compared to other prescription medications for chronic idiopathic constipation.
- ANI Pharmaceuticals has launched Estradiol Gel, 0.06%, after receiving final FDA approval for its Abbreviated New Drug Application, expanding its product portfolio. - The newly launched product is a generic version of EstroGel Gel, 0.06%, providing a more affordable alternative for patients requiring estradiol therapy. - According to IQVIA data, the U.S. annual sales for Estradiol Gel, 0.06% total approximately $16.7 million, indicating a substantial market opportunity for ANI Pharmaceuticals.
